이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

중국 PNH에 대한 실제, 다기관, 전향적 관찰 연구 (ReWoPNH)

2026년 9월 22일 업데이트: AstraZeneca

중국의 발작성 야간 혈색소뇨증(PNH)에 대한 실제 세계, 다기관, 전향적 관찰 연구

As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.

연구 개요

상태

완전한

정황

상세 설명

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare and life-threatening acquired disorder of the pluripotent hematopoietic stem cell and therefore can affect erythrocytes, leukocytes, thrombocytes and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in the phosphatidylinositol glycan class A (PIG-A) This gene is required for the synthesis of the glycosyl phosphatidyl-inositol (GPI) anchor, which is necessary to attach some proteins to the blood cell membrane. Therefore, a lack of two important complement regulatory proteins is observed on the cell surface: 'decay-accelerating factor' (DAF), also called 'CD55' and 'membrane inhibitor of reactive lysis' (MIRL), also called 'CD59' Thus, red blood cells are more vulnerable to the attack by the complement activation product MAC (complement membrane attack complex). This leads to a complement-mediated intravascular hemolysis. The predisposition of venous thrombosis, hemolytic anemia, complete thrombocytopenia, and thrombosis are the three main characteristics of the disease. Its incidence is not really known but estimated at 0.1~0.6/100 000 per-sons/yr, and prevalence is estimated at 1~4 cases/100,000 persons/yr. PNH was listed in the First Catalogue of Rare Diseases in China, and its incidence was previously reported to be 1/100,000 persons/year, peak onset age 20~40 years.

PNH can be classified into 3 different forms: classical PNH, PNH associated with aplastic anemia (PNH-AA), and subclinical PNH, based on clinical features, bone marrow characteristics, and the size of the mutant clone. The traditional treatment of PNH is still aimed at "protecting" the PNH clone, reducing complement attack and destruction, and alleviating hemolysis with symptomatic supportive therapy. In acute hemolytic episodes, could be administered adrenal glucocorticoids, complemented by cell membrane stabilizers, folic acid, and alkaline drugs. In case of PNH-AA syndrome, treatment with androgens and immunosuppressants may be used; anticoagulation and heparin therapy should be given for the occurrence of thrombosis; other symptomatic supportive treatments include transfusion of red blood cells and platelets if necessary as well as antibacterial drugs in case of infection. Bone marrow transplantation is the only curative therapy for PNH presupposes, but patient need to achieve complete remission with chemotherapy first and a suitable donor is needed.

Besides supportive care, global guidance/consensus also recommend C5 complement inhibitor Eculizumab as a treatment method, and its use could significantly improve 5-year survival rate to 95.5%. Eculizumabis a humanized, first-in-class, anti-C5 antibody that binds with high affinity to C5 and blocks the terminal complement-C5a and C5b-9 formation, reducing the chronic uncontrolled complement activation and its consequences. Eculizumab has been approved for PNH by National Medical Products Administration in August, 2022.

연구 유형

관찰

등록 (실제)

724

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Hangzhou, 중국
        • Research Site
    • Anhui
      • Hefei, Anhui, 중국, 230002
        • Research Site
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100000
        • Research Site
      • Beijing, Beijing Municipality, 중국, 100044
        • Research Site
    • Guangdong
      • Guangzhou, Guangdong, 중국, 510080
        • Research Site
      • Guangzhou, Guangdong, 중국, 510180
        • Research Site
      • Guangzhou, Guangdong, 중국, 510515
        • Research Site
    • Guangxi
      • Nanning, Guangxi, 중국, 530021
        • Research Site
    • Guizhou
      • Guiyang, Guizhou, 중국, 550004
        • Research Site
    • Hebei
      • Shijiazhuang, Hebei, 중국, 050000
        • Research Site
    • Heilongjiang
      • Harbin, Heilongjiang, 중국, 150001
        • Research Site
    • Henan
      • Zhengzhou, Henan, 중국, 450003
        • Research Site
      • Zhengzhou, Henan, 중국, 450052
        • Research Site
      • Zhengzhou, Henan, 중국, 463599
        • Research Site
    • Hubei
      • Wuhan, Hubei, 중국, 430030
        • Research Site
      • Wuhan, Hubei, 중국, 430000
        • Research Site
    • Hunan
      • Changsha, Hunan, 중국, 410008
        • Research Site
      • Changsha, Hunan, 중국, 410005
        • Research Site
    • Jiangsu
      • Nanjing, Jiangsu, 중국, 210029
        • Research Site
      • Nantong, Jiangsu, 중국, 226001
        • Research Site
      • Xuzhou, Jiangsu, 중국, 221002
        • Research Site
    • Jiangxi
      • Nanchang, Jiangxi, 중국, 330006
        • Research Site
      • Nanchang, Jiangxi, 중국, 330008
        • Research Site
    • Jilin
      • Changchun, Jilin, 중국, 130021
        • Research Site
    • Liaoning
      • Shenyang, Liaoning, 중국, 110001
        • Research Site
    • Shandong
      • Jinan, Shandong, 중국, 250000
        • Research Site
      • Qingdao, Shandong, 중국, 266000
        • Research Site
      • Zibo, Shandong, 중국, 255090
        • Research Site
    • Shangdong
      • Linyi, Shangdong, 중국, 276034
        • Research Site
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, 중국, 200040
        • Research Site
      • Shanghai, Shanghai Municipality, 중국, 200336
        • Research Site
    • Shanxi
      • Taiyuan, Shanxi, 중국, 030000
        • Research Site
      • Xi’an, Shanxi, 중국, 710061
        • Research Site
      • Xi’an, Shanxi, 중국, 710068
        • Research Site
    • Sichuan
      • Chengdu, Sichuan, 중국, 610041
        • Research Site
      • Chengdu, Sichuan, 중국, 610072
        • Research Site
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, 중국, 300020
        • Research Site
      • Tianjin, Tianjin Municipality, 중국, 300052
        • Research Site
      • Tianjin, Tianjin Municipality, 중국, 300190
        • Research Site
    • Yunnan
      • Kunming, Yunnan, 중국, 650034
        • Research Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Study Population:

Number of patients (estimate): 1000; Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

설명

Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Hemolysis:Concentration of LDH changes at each visit from base-line, of all patients
기간: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with thrombosis within follow-up
기간: 12 months

To characterize the progression of PNH

12 months
average number of units of packed RBCs transfused per month, of all patients
기간: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with renal failure within follow-up
기간: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with pulmonary hypertension within follow-up
기간: 12 months

To characterize the progression of PNH

12 months

2차 결과 측정

결과 측정
측정값 설명
기간
Number and percentage of patients with each symptom of interest within follow-up
기간: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Demographics at baseline of all patients
기간: baseline

To describe clinical characteristics of patients with PNH in China

baseline
Number and percentage of patients receiving each type of treatment method at baseline and each visit within follow up, including glucocorticoid, red blood cell transfusion, other supportive treatment, bone marrow transplant, eculizumab, of all patients
기간: 12 months

To describe the treatment pattern of PNH in China

12 months
All serious adverse events (SAEs)of PNH among eculizumab-treated patients
기간: 12 months

To describe the safety of Eculizumab treatment via Serious Adverse Events

12 months
Standard descriptive statistics of pregnancy status
기간: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of lactation status
기간: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of PNH classification
기간: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of flow cytometry results
기간: 12 months

To describe clinical characteristics of patients with PNH in China

12 months

기타 결과 측정

결과 측정
측정값 설명
기간
Concentration of LDH changes at each visit from base-line of PNH among eculizumab-treated patients
기간: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with thrombosis within follow up among eculizumab-treated patients
기간: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
average number of units of packed RBCs transfused per month within 12 months v
기간: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with renal failure within follow up among eculizumab-treated patients
기간: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with pulmonary hypertension (PH) within follow up among eculizumab-treated patients
기간: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 11월 10일

기본 완료 (실제)

2025년 12월 3일

연구 완료 (실제)

2025년 12월 3일

연구 등록 날짜

최초 제출

2023년 10월 30일

QC 기준을 충족하는 최초 제출

2023년 11월 23일

처음 게시됨 (실제)

2023년 12월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 22일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

키워드

기타 연구 ID 번호

  • D7414R00001

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD 공유 기간

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 공유 액세스 기준

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .